Profile: Emergent BioSolutions Inc (EBS)
22 Nov 2017
Emergent BioSolutions Inc., incorporated on December 19, 2003, is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. The Company focuses on developing, manufacturing and commercializing medical countermeasures (MCM) that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear (CBRN), as well as explosive-related threats and emerging infectious diseases (EID). The Company operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing.
Vaccines and Anti-infectives
The Company's Vaccines and Anti-infectives business unit consists of BioThrax (Anthrax Vaccine Adsorbed), which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. The NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant) is also an anthrax vaccine. UV-4B, a novel anti-viral therapeutic is developed as an oral treatment for dengue and influenza infections. GC-072, the lead compound in the EV-035 series of antibiotics is developed as an oral and intravenous treatment for Burkholderia pseudomallei infection.
The Company's Antibody Therapeutics business unit consists of marketed products, such as Anthrax Immune Globulin Intravenous (Human) (Anthrasil), Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine) (BAT), and Vaccinia Immune Globulin Intravenous (Human) (VIGIV). Anthrasil is a polyclonal antibody therapeutics for the treatment of inhalational anthrax. BAT is the heptavalent therapeutics for the treatment of botulinum disease. VIGIV the therapeutics used to address certain complications from smallpox vaccination. Within its Antibody Therapeutics business unit it offers hyperimmune platform technology to address PHTs, including the stage product candidates, such as FLU-IG (NP025), which is a human polyclonal antibody therapeutic developed to treat seasonal influenza; ZIKA-IG (NP024), which is a human polyclonal antibody therapeutic developed as a prophylaxis and treatment for Zika infections, and FILOV (NP026), which is an equine polyclonal antibody therapeutic developed to treat hemorrhagic fever caused by Filoviruses (Ebola, Marburg and Sudan).
The Company's Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride). RSDL is a device used to remove or neutralize chemical warfare agents and T-2 toxins from the skin. Trobigard is an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride, which is a nerve agent countermeasure. Within its Devices business unit it provides auto-injector platform to develop several investigational-stage product candidates, including a device filled with pralidoxime chloride and atropine sulfate, which is designed for intramuscular use as an adjunct to atropine in the treatment of poisoning by nerve agents having anticholinesterase activity.
The Company's Contract Manufacturing business unit consists of contract manufacturing services to third-party customers. These services, which are performed at its facilities located at sites in Baltimore, Maryland and Winnipeg, Manitoba, Canada, include pharmaceutical product development, manufacturing, filling services for injectable and other sterile products, process design, technical transfer, manufacturing validations, laboratory support, aseptic filling, lyophilization, final packaging and accelerated and ongoing stability studies. The Company manufactures both vial and pre-filled syringe formats and it produces bulk drug product and finished units of clinical and commercial drugs. It provides these services for various drug products, such as small molecule, biological, and blood products in all stages of development and commercialization. Its fill/finish facility in Baltimore, Maryland is an approved or inspected manufacturing facility under the regulatory regimes in the United States, Canada, Japan, Brazil, the Middle East and several countries in the European Union. It also focuses on marketing the available biologics bulk product manufacturing out of certain facilities located at its site in Lansing, Michigan.
The Company competes with PharmAthene, Inc., PaxVax Inc., Altimmune, Inc., Pfenex Inc., Soligenix, Inc., Immunovaccine Inc., NanoBio Corporation, GlaxoSmithKline plc, Elusys Therapeutics, Inc., SIGA Technologies, Inc. Lonza Group Ltd., OSO BioPharmaceuticals Manufacturing, LLC, Par Pharmaceutical Companies, Inc., Jubilant Life Sciences Limited, Patheon Inc., Hospira Inc., Cook Group Inc. and Ajinomoto Co., Inc.
Emergent BioSolutions Inc
400 Professional Dr Ste 400
GAITHERSBURG MD 20879-3457
Company Web Links
- BRIEF-Emergent Biosolutions reports third quarter results
- BRIEF-Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 mln to supply nerve agent antidote auto-injector
- BRIEF-Emergent Biosolutions completes acquisition of Raxibacumab from GSK
- BRIEF-Emergent BioSolutions signs five-year follow-on contract with DoD valued at up to $171 mln
- BRIEF-Emergent BioSolutions awarded $63 mln BARDA contract to develop treatment for cyanide exposure